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Abstract By secreting insulin and glucagon, the β- and α-cells of the pancreatic islets play a
central role in the regulation of systemic metabolism. Both cells are equipped with ATP-regulated
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potassium (KATP) channels that are regulated by the intracellular ATP/ADP ratio. In β-cells, KATP
channels are active at low (non-insulin-releasing) glucose concentrations. An increase in glucose
leads to KATP channel closure, membrane depolarization and electrical activity that culminates
in elevation of [Ca2+]i and initiation of exocytosis of the insulin-containing secretory granules.
The α-cells are also equipped with KATP channels but they are under strong tonic inhibition at
low glucose, explaining why α-cells are electrically active under hypoglycaemic conditions and
generate large Na+- and Ca2+-dependent action potentials. Closure of residual KATP channel
activity leads to membrane depolarization and an increase in action potential firing but this
stimulation of electrical activity is associated with inhibition rather than acceleration of glucagon
secretion. This paradox arises because membrane depolarization reduces the amplitude of the
action potentials by voltage-dependent inactivation of the Na+ channels involved in action
potential generation. Exocytosis in α-cells is tightly linked to the opening of voltage-gated
P/Q-type Ca2+ channels, the activation of which is steeply voltage-dependent. Accordingly,
the inhibitory effect of the reduced action potential amplitude exceeds the stimulatory effect
resulting from the increased action potential frequency. These observations highlight a pre-
viously unrecognised role of the action potential amplitude as a key regulator of pancreatic islet
hormone secretion.
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Abstract figure legend The confocal images of a mouse pancreatic islet with β-cells in red (top left), α-cells in green
(middle left) and merged image (bottom left). The images were taken at the top of an islet using an upright confocal
microscope, which is why a clear separation of the β- and α-cells is not as evident as in the centre of the islet. Panels
to the right show the effects of KATP channel closure on electrical activity in β- (top right) and α-cells (middle right).
The schematic (lower right) summarizes the relationship between KATP channel closure/electrical activity on insulin and
glucagon secretion. A decrease in KATP channel activity leads to a biphasic stimulation of insulin secretion (from a low
basal value) but inhibition of glucagon secretion (from a high basal rate) despite similar effects on electrical activity in
α- and β-cells. This Topical Review discusses this paradox.
Introduction
In most cells, potassium (K+) channel activity constitutes
the principal background membrane conductance,
which explains why the resting membrane potential
usually approximates the K+ equilibrium potential (EK;
-70 mV). In general, an increase in K+ channel activity
lowers electrical excitability by clamping the membrane
potential at EK and reducing the input resistance; both
factors making it more difficult for the cell to generate
action potentials. Conversely, a decrease in K+ channel
activity increases electrical excitability by producing
membrane depolarization and increasing the membrane
resistance. Under the latter conditions, the opening of
individual Na+ or Ca2+ channels may suffice for the cell
to depolarize to the threshold for action potential firing
(Fenwick et al. 1982).
ATP-sensitive potassium (KATP) channels are expressed
in a number of cells including cardiomyocytes, skeletal
muscle, smooth muscle cells and certain neurones (Huang
et al. 2019). However, their role is particularly evident
in the β-cells of the pancreatic islets (Ashcroft, 2007).
The pancreatic islets represent the endocrine part of the
pancreas and make up about 1% of its mass, corresponding
to 1 g in humans (Rorsman & Ashcroft, 2018). The islets
are micro-organs consisting of (on average) 200 end-
ocrine cells: insulin-producing β-cells (75% of islet cells)
and glucagon-producing α-cells (15–20%). In addition,
there are a small number (5%) of somatostatin-releasing
δ-cells. Insulin and glucagon are the body’s principal
glucose-regulating hormones (Frayn & Evans, 2019).
They are released in response to increases (hyper-
glycaemia) and decreases (hypoglycaemia) in plasma
glucose concentrations, respectively. Collectively they
ensure that plasma glucose is maintained at 5 mM in
humans.
In β-cells, an increase in plasma glucose (for
example, following ingestion of a carbohydrate-rich meal)
stimulates insulin secretion by closing KATP channels
(Rorsman & Ashcroft, 2018). Intriguingly, KATP channels
are also found in the glucagon-secreting α-cells (Bokvist
et al. 1999). Given the reciprocal regulation of insulin and
glucagon secretion by glucose, the question arises as to
how KATP channel closure stimulates secretion in β-cells
but inhibits it in α-cells. In this Topical Review we consider
this conundrum.
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KATP channels
KATP channels are octameric heterocomplexes of four
KIR6.2 (encoded by Kcnj11) and four SUR1 (encoded
by Abcc8) subunits (Seino, 1999). They are regulated by
variations of the intracellular ATP concentrations: they
are active in the absence of ATP and are inhibited by
increasing concentrations of ATP with an IC50 of 10μM
in both α- and β-cells (Cook & Hales, 1984; Bokvist et al.
1999). KATP channels closed by ATP can be reactivated
by Mg-ADP (Dunne & Petersen, 1986; Kakei et al. 1986)
and in the intact cell the channel activity is therefore
believed to be regulated by the submembrane ATP/ADP
ratio.
The KATP channel is the molecular target of the hypo-
glycaemic sulphonylureas (SUs) (Trube et al. 1986),
compounds that have been used to treat type-2 diabetes
(T2D) since the early 1950s. Tolbutamide is an example
of the first generation SUs and blocks the KATP
channels with an IC50 of 7 μM; second generation
SUs (like glibenclamide) inhibit channel activity at
nanomolar concentrations. Conversely, the KATP channels
are activated by K+ channel openers such as diazoxide,
which activates the channel with an EC50 of 20–30 μM in
β- and α-cells (Zunkler et al. 1988; Zhang et al. 2013).
Because of its central role in the control of systemic
metabolism, the β-cell can be regarded as the archetypal
metabolically regulated cell. We will therefore start by
summarizing the role of the KATP channel in insulin
secretion. We will then consider the more controversial
role of KATP channels in the glucagon-secreting α-cell
against the backdrop of the β-cell. There are several
excellent reviews on the structure and function of the KATP
channels and the respective roles of the two subunits in
its regulation (Seino, 1999; Nichols, 2006; McTaggart et al.
2010). These aspects will therefore not be reviewed here.
KATP channels in metabolic sensing:
the β-cell
β-cell electrical activity is tightly correlated with insulin
secretion (Rorsman & Ashcroft, 2018). At low (1 mM)
glucose (when insulin secretion is suppressed), the
β-cell is hyperpolarised (-70 mV) and electrically silent.
Increasing glucose to concentrations 6 mM (i.e. close
to the normal plasma glucose levels) induces membrane
depolarization. When the membrane potential reaches
a threshold of -50 mV, the β-cells start generating
oscillatory electrical activity consisting of bursts of
action potentials that originate from depolarized plateaux
separated by electrically silent repolarized intervals. The
bursts of action potentials leads to increases in [Ca2+]i
that trigger exocytosis of the insulin-containing secretory
granules by mechanisms similar to those involved in
neurotransmitter release (Fig. 1A and C) (Rorsman
& Ashcroft, 2018). As in neurones, exocytosis of the
insulin-containing granules appears to be determined by
the local [Ca2+]i in close proximity to the inner mouth
of the Ca2+ channels (Pertusa et al. 1999; Barg et al.
2001).
In β-cells, the glucose-induced membrane
depolarization and associated initiation of action
potential firing are mediated by changes in KATP channel
activity. Under hypoglycaemic conditions, KATP channel
activity is high because of a low cytoplasmic ATP/ADP
ratio and the combination of a negative membrane
potential and low membrane resistance prevents electrical
activity. When plasma glucose rises, accelerated glucose
uptake into the β-cells and the associated stimulation of
metabolism increase the cytoplasmic ATP/ADP ratio and
thereby causes KATP channel closure.
When KATP channel activity is reduced, the β-cells
depolarize because the residual K+ permeability is no
longer sufficient to counteract the depolarizing influence
of other membrane conductances that were previously
too small to affect the membrane potential. The identity
of the depolarizing background membrane conductance
remains to be unequivocally identified; candidates include
TRPM2 or Piezo1 (Yosida et al. 2014; Deivasikamani
et al. 2019) and/or Cl−-permeable LRRC8 channels
(also known as SWELL1 or VRAC) (Stuhlmann et al.
2018).
As reviewed previously (Rorsman & Ashcroft, 2018),
β-cell electrical activity reflects the activation of
voltage-gated Ca2+ and K+ channels, which underlie the
up- and downstroke of the action potential, respectively.
In mouse β-cells, the Ca2+ channels are L- and R-type
whereas in human β-cells, L- and P/Q-type Ca2+ channels
predominate. Voltage-gated Na+ channels also contribute
but mainly at glucose concentrations just above the
threshold for insulin secretion (Braun et al. 2008).
However, in mouse β-cells the Na+ channels exhibit an
unusual voltage dependence of inactivation and in most
cells they are completely inactivated at the normal resting
potential of -70 mV (Zhang et al. 2014; Godazgar et al.
2018).
The repolarization of the action potential results from
the opening of Kv2.1 (mouse) or Kv2.2 (human) and
large-conductance Ca2+-activated K+ channels (Jacobson
et al. 2007; Braun et al. 2008; Houamed et al. 2010).
Pharmacological inhibition of the voltage-gated K+
channels amplifies glucose-induced insulin secretion by
increasing the duration and amplitude of the action
potentials (Rorsman et al. 2011).
The oscillatory electrical activity seen at the inter-
mediate glucose concentration and its conversion into
uninterrupted action potential reflects the complex
cross-talk between Ca2+ entry, intracellular Ca2+ ATPase
activity and Ca2+-induced (via changes in the ATP/ADP
ratio) of KATP channel activity (Kanno et al. 2002).
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Like glucose, SUs promptly and reversibly depolarize
the β-cell and initiate action potential firing in β-cells
(Fig. 1B), which accounts for their insulin-releasing
capacity. When applied at intermediate glucose
concentrations (10 mm), they also convert oscillatory
electrical activity into continuous action potential firing
(Henquin, 1988; Kanno et al. 2002), in keeping with
the idea that electrical activity transiently reactivates
KATP channels until the intracellular ATP/ADP ratio has
been restored (Tarasov et al. 2012). Conversely, addition
of the KATP channel activator diazoxide suppresses
glucose-induced electrical activity in β-cells (Henquin
& Meissner, 1982). Two important conclusions can be
drawn from these observations: First, KATP channel closure
is involved in both the initiation and modulation of
β-cell electrical activity. Second, there must be sufficient
depolarizing background in β-cells even at low glucose to
account for the rapid initiation of electrical activity upon
addition of SUs.
Following its release into the bloodstream, secreted
insulin acts on the target organs (chiefly the liver) where
it promotes glucose storage until normal blood glucose
is restored. When this has occurred, insulin secretion
stops by the reversal of the process described above. Thus,
insulin secretion is under feedback control via changes in
plasma glucose (Fig. 1C).
Variations on the KATP channel theme:
the α-cell
As mentioned above, the glucagon-producing α-cells are
also equipped with KATP channels. At the molecular level,
they are identical to those in β-cells and they are similarly
influenced by ATP and ADP (Bokvist et al. 1999). Unlike
β-cells, α-cells are electrically active at low (1 mM), or
even the complete absence of, glucose (Gopel et al. 2000).
A role for the KATP channels in α-cells may seem counter-
intuitive given that glucose reciprocally regulates insulin
and glucagon secretion. However, studies in KATP channel
knockout mice firmly establish their role in glucagon
secretion. In islets from such mice, glucagon secretion












































































Figure 1. KATP channels in β-cells
A, electrical activity in β-cells evoked by an
increase in plasma glucose from 1 to 10 mM.
B, as in A but tolbutamide (0.2 mM) applied
instead of glucose. C, schematic of consensus
model of glucose-induced insulin secretion in
β-cells. Glut1/2, glucose transporters 1 and 2
(human and mouse, respectively); KATP
channels, ATP-sensitive K+ channels; ,
membrane potential; SG, secretory granules.
The + and - signs denote stimulation and
inhibition, respectively, whereas the arrows
(↑,↓) indicate an increase or decrease of the
indicated parameter. The red arrow indicates
feedback regulation of insulin secretion via
changes in plasma glucose due to (for
example) hepatic glucose disposition.
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tolbutamide have (unlike what is seen in control islets)
little or no further glucagonostatic effect (Gromada et al.
2004; Munoz et al. 2005; Shiota et al. 2005; MacDonald
et al. 2007; Cheng-Xue et al. 2013). We acknowledge
that glucagon secretion may also be under paracrine
regulation by insulin (Unger & Orci, 2010) or somatostatin
(Hauge-Evans et al. 2009). Indeed, it is possible that the
small inhibition that persists in KATP channel-deficient
islets (10% of that in control islets) (Cheng-Xue et al.
2013) reflects such paracrine actions. However, whilst
somatostatin may contribute to the glucagonostatic effect
at high glucose concentrations that are associated with
stimulation of somatostatin secretion, its role at low
glucose (when somatostatin release is low) must be limited
(Zhang et al. 2007; Briant et al. 2017; Lai et al. 2018; Kellard
et al. 2020). Here we will therefore focus on the alternative
possibility that the glucagonostatic actions of glucose and
tolbutamide reflect direct effects within the α-cell itself
and that they are mediated by inhibition of KATP channels.
KATP channels in α-cells vs. β−cells:
quantitative aspects
Glucagon secretion is traditionally measured in isolated
intact pancreatic islets. Many of the earlier studies that
suggest little role for the KATP channels in α-cells were
conducted on isolated cells maintained in tissue culture
(Barg et al. 2000; Quoix et al. 2009), which may not
be fully representative of the situation in vivo. When
KATP channel activity is instead measured in α-cells
in acutely isolated intact islets, the resting membrane
conductance was found to be 270 pS at 1 mM glucose and
reduced to 200 pS after application of tolbutamide or
increasing glucose to 6 mM (the concentration producing
maximal inhibition of glucagon secretion) (Zhang et al.
2013). The corresponding values in β-cells are 4 nS and
1 nS (Gopel et al. 1999). Thus, the net whole-cell KATP
conductance in α-cells is only 70 pS at 1 mM glucose
(2% of the 3 nS in β-cells). It is likely that most
of the residual KATP-independent (tolbutamide-resistant)
membrane conductance largely reflects ‘leak’ across the
lipid membrane itself and around the recording electrode
as it is not affected by any experimental manipulation and
the giga-seal typically has a resistance of 5–10 G (i.e.
100–200 pS) (Hamill et al. 1981).
Strong tonic inhibition of KATP channels in α-cells
at low glucose
The low resting conductance of α-cells explains why they
are electrically active at low glucose. Importantly, it is
not simply a consequence of a low expression of the
KATP channel in α-cells. The KATP channel density can be
estimated from the increase in K+ conductance following
the wash-out of intracellular ATP. Such experiments reveal
that the KATP channel density (normalised to membrane
area) is, if anything, considerably higher in α-than in
β-cells (Bokvist et al. 1999), in agreement with gene
expression data (DiGruccio et al. 2016). This suggests
that the KATP channels must be under strong tonic
inhibition even in α-cells exposed to low glucose. Exactly
how this occurs remains to be elucidated but it may
reflect effective metabolism of fatty acids in α-cells under
hypoglycaemic conditions (Briant et al. 2018). Carnitine
palmitoyltransferase 1 (CPT1) is a mitochondrial trans-
membrane enzyme responsible for the formation of
acyl-carnitine from long-chain acyl-coenzyme A. This
enzyme is considered rate-limiting for β-oxidation of
long-chain fatty acids. In mice that lack CPT1 in the
α-cells, glucagon secretion at 1 mM glucose is reduced
by 40%. Thus, there is a redundancy of ATP-producing
mechanisms in α-cells. It is therefore of interest that
α-cells (unlike β- and δ-cells) also express the low-Km
hexokinase-1 (Hk1) in addition to glucokinase (Gck; a
high-Km hexokinase). Genetic ablation of glucokinase
in α-cells has no effect on α-cell electrical activity
and glucagon secretion at low (1 mM) glucose but
abolishes the glucagonostatic effect of high (6 and 20 mM)
glucose (Basco et al. 2018). However, the impact of
genetically ablating hexokinase-1 in α-cells has not yet
been investigated.
Although α-cell KATP channel activity in the absence of
glucose is very low, it is greater than zero; the observed
net membrane conductance of 70 pS is equivalent to an
average of five KATP channels being active in the entire cell,
suggesting that the open probability of the α-cell’s >1000
KATP channels (Bokvist et al. 1999) is <0.5%. However,
even a KATP channel activity as low as this is sufficient to
keep the α-cell membrane potential partially repolarized
(-55 mV) as witnessed by the 10–15 mV depolarization
observed when the channels are inhibited by tolbutamide
(Fig. 2A) or high glucose (Zhang et al. 2013;
Babinsky et al. 2017). As in β-cells, this depolarization
increases action potential firing in α-cells but this is
associated with a suppression rather than stimulation of
glucagon secretion. Below we discuss how this paradox
arises.
Functional consequences of KATP channel closure: role
of voltage-gated Na+ and Ca2+ channels
Glucagon secretion in α-cells is the product of action
potential frequency and the amount of glucagon secreted
for each action potential. Normally, each action potential
evokes glucagon granule exocytosis, albeit with a
probability as low as 0.004 granules/action potential
(Fig. 2B). Following the application of tolbutamide,
the release probability is reduced by 80% (to 0.0008
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granules/action potential) and although there is a 150%
increase in action potential frequency, the combination
of these effects produces a net 50% decrease in glucagon
secretion (Zhang et al. 2013).
Why is the release probability reduced? The action
potentials in α-cells reflect the activation of voltage-gated
Na+ channels and P/Q-type Ca2+ channels. Na+ channels
(including those in α-cells) (Zhang et al. 2014) have a
dual dependence on membrane potential: depolarization
both activates and inactivates the channels. Unlike what is
observed in β-cells where most (if not all) Na+ channels
are locked in the inactivated state, Na+ channels in α-cells
exist in an ‘activatable’ state (Zhang et al. 2014). The
α-cells express Nav1.3 Na+ channels whereas Nav1.7 pre-
dominates in β-cells but this difference is only part of
the reason why the Na+ currents in the α-cells inactivate
at 50 mV more depolarized membrane potentials than






























































































     


















Figure 2. KATP channels in α-cells
A, effects of tolbutamide (200 μM) on action potential firing in an α-cell within a mouse islet exposed to 1 mM
glucose. Note that the α-cell is electrically active and that tolbutamide leads to membrane depolarization and
increases action potential firing. B, schematic of α-cell action potentials at 1 mM glucose in the absence and
presence of tolbutamide; membrane potential (V) shown in top trace (black) and membrane currents flowing
through voltage-gated Na+ channels (INa; blue) and P/Q-type Ca2+ channels (ICa(P/Q); red) are indicated. The
table (inset, right) summarizes the action potential (AP) frequency (freq.; taken from Zhang et al. (2013)), release
probability (prob.) and fractional glucagon release (% of content/h; estimated from reported glucagon secretion
rates and islet glucagon contents (Knudsen et al. 2019)) and converted to number of granules released based on
each α-cell containing 7000 granules (Barg et al. 2000). C, schematic of effects of glucose and tolbutamide on
electrical activity and glucagon secretion in α-cells at low glucose (left) and at high glucose or in the presence of a
high dose of SU (right). At low glucose, KATP channel activity is low but >0 and this keeps the membrane potential
() of the α-cell sufficiently depolarized to allow AP firing whilst preventing voltage-dependent inactivation of the
voltage-gated Na+ channels (Na[V]). The large-amplitude action potentials activate the P/Q-type Ca2+ channels
(Ca[P/Q]). The associated increase in [Ca2+]i triggers exocytosis of glucagon-containing secretory granules (SGs).
When glucose is elevated, increased glucose uptake via Glut1 or 3 and the associated increase in ATP/ADPi, KATP
channel activity fall to zeros, resulting in strong membrane depolarization, inactivation of the Na(V) channels,
reduced AP amplitude, less Ca2+ entry via Ca(P/Q) activation and a fall in [Ca2+]i, culminating in suppression of
glucagon secretion. It is also possible that a glucose metabolite directly modulates Ca(P/Q) and thereby reduces
Ca2+ entry and glucagon secretion (indicted by ‘?’). Diazoxide may reverse the glucagonostatic effect of high
glucose by activation of KATP channels (black arrow) when used at an appropriate concentration leading to an
increase in channel activity comparable to the decrease produced by glucose. D, relationship between whole-cell
KATP channel conductance (G) and glucagon secretion. The black arrow indicates changes in KATP channel activity
and the resulting change in glucagon secretion when glucose is increased from 1 to 6 mM (arrow). The red curve
was estimated by parallel measurements of glucagon secretion at 6 mM glucose in the presence of increasing
concentrations of diazoxide (1–100 μM). Data in panel D from Zhang et al. (2013) (redrawn).
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-100 mV); most of the discrepancy is instead attributable to
differences in the Na+ channels’ lipid environment in the
α- and β-cell plasma membranes (Godazgar et al. 2018).
The central role of Na+ channels in the glucagon secretion
at low glucose is underscored by the strong inhibition of
glucagon secretion produced by the Na+ channel blocker
tetrodotoxin (TTX) (Zhang et al. 2013, 2014).
Because of Na+ channel inactivation, the peak voltage
of the action potentials declines from +10 mV when the
membrane potential is -55 mV (or more negative) to
-10 mV when the membrane potential is -45 mV (or more
positive). This change in peak voltage is highly significant
because exocytosis in α-cell is steeply voltage-dependent,
largely reflecting the voltage dependence of the P/Q-type
Ca2+ channels that mediate the Ca2+ entry for glucagon
secretion at low glucose (Fig. 2B). The change in
action potential amplitude produced by application
of tolbutamide can be estimated to reduce glucagon
exocytosis by 80% (Zhang et al. 2013), similar to
the estimated reduction of glucagon granules’ release
probability (see above).
It is implicit from the model that exocytosis of the
glucagon granules is regulated by [Ca2+]i close to the
inner mouth of the P/Q-type Ca2+ channels. This is
supported by the findings that exocytosis is resistant
to intracellular application of millimolar concentrations
of the Ca2+ chelator EGTA (Zhang et al. 2013). It
remains an open question whether hyperglycaemia
inhibits glucagon secretion exclusively by the same
(membrane potential-dependent) mechanism or whether
glucose metabolism additionally modulates P/Q-type
Ca2+ channel activity by a more direct inhibitory effect.
The latter possibility is suggested by studies on the
glucagonostatic effects of the incretin hormone GLP-1
(De Marinis et al. 2010). Such a direct modulatory effect
of glucose would be consistent with the observation
that glucose inhibits glucagon secretion evoked by high
K+ (70 mM) stimulation in human islets (Ramracheya
et al. 2018) (Fig. 2C), an effect that clearly cannot be
accounted for by modulation of action potential height.
Whether this also applies to mouse α-cells and the under-
lying mechanism have not been elucidated. However,
it is clear that the glucose-induced changes in action
potential height are sufficient to account for most of the
glucagonostatic effect of high glucose but this does not
exclude the contribution of additional mechanisms.
Voltage-gated K+ channels
Action potential repolarization in α-cells is mediated
by the activation of voltage-gated K+ currents. Gene
expression and electrophysiological data suggest evidence
for the presence of Kv2.1/2.2 and Kv11.1/11.2 delayed
rectifying and Kv4.1 (mouse) and Kv4.3 (human)
A-type K+ currents. Unlike what is observed in β-cells,
pharmacological inhibition of these channels in α-cells
leads to suppression of glucagon secretion at 1 mM
glucose (Gromada et al. 2004; Ramracheya et al. 2010;
Spigelman et al. 2010), possibly by resulting in a more
depolarized interspike voltage that prevents complete Na+
channel reactivation between the action potentials (Braun
& Rorsman, 2010).
Bell-shaped relationship between KATP channel
activity and glucagon secretion: impact of
pharmacological activation of KATP channels
If tolbutamide inhibits glucagon secretion, the KATP
channel opener diazoxide should have the opposite effect.
Indeed, when tested at low concentrations, diazoxide
reverses the glucagonostatic effect of high glucose by
reversal of the process shown in Fig. 2C. Notably,
the concentration of diazoxide that stimulates glucagon
secretion must be carefully titrated and depends on
the experimental conditions such as the concentration
of bovine serum albumin (commonly included in the
extracellular medium in glucagon secretion studies). At
high concentrations, the repolarizing effect may become
so strong that any stimulatory effect on glucagon secretion
due to the increase in action potential height might be
cancelled out by the inhibition (partial or complete) of
action potential firing. Collectively, these considerations
suggest that there is a bell-shaped relationship between
KATP channel activity and glucagon secretion (Fig. 2D).
This concept may – as we will elaborate below –
have important implications for the understanding of
the dysregulation of glucagon secretion associated with
diabetes.
Role of [Ca2+]i in glucagon secretion
As discussed above, changes in KATP channel activity
modulate action potential firing in α-cells. Because
electrical activity involves the opening of voltage-gated
Ca2+ channels, electrical activity in α-cells is associated
with oscillations in [Ca2+]i (Kellard et al. 2020). Despite
the robust inhibitory effects of high glucose on glucagon
secretion this associates with surprisingly subtle effects
on [Ca2+]i (Nadal et al. 1999; Quoix et al. 2009; Le
Marchand & Piston, 2012; Zhang et al. 2013; Li et al. 2015)
and although a glucose-induced reduction of [Ca2+]i is
observed in some cells, it continues to oscillate in other
cells (Fig. 3A). A similar variability is observed in the
responses to tolbutamide when the compound is tested
in intact islets (Fig. 3B) (Quesada et al. 1999). This
has led to the suggestions that glucagon is regulated
distal to the elevation of [Ca2+]i by a direct effect
on exocytosis (Hughes et al. 2018). Recently, based
on imaging of several hundreds of α-cells, we were
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able to demonstrate that (despite a great cell-to-cell
variability) increasing glucose from 1 to 6 mM produced
a statistically significant reduction of [Ca2+]i manifested
as a reduction of both frequency and amplitude of
[Ca2+]i oscillations (Kellard et al. 2020). The effect
on the amplitude of the [Ca2+]i oscillations resembles
that produced by blocking the subset of Ca2+ channels
(P/Q-type) linked to glucagon secretion at low glucose
(De Marinis et al. 2010), in keeping with the idea
that the effect of glucose culminates in reduced Ca2+
entry.
In addition to the P/Q-type Ca2+ channels, α-cells are
also equipped with L-type Ca2+ channels. Although these
channels contribute to action potential firing in α-cells,
blocking them with isradipine or nifedipine does not
affect glucagon secretion at 1 mM glucose (MacDonald
et al. 2007; De Marinis et al. 2010). However, L-type Ca2+
channels play a key role in glucagon secretion evoked by
adrenaline (and presumably other agents increasing intra-
cellular cAMP) (De Marinis et al. 2010) by promoting
intracellular Ca2+ release (Hamilton et al. 2018).
Consistent with a bell-shaped relationship between
KATP channel activity and α-cell [Ca2+]i/glucagon
secretion, diazoxide abolished [Ca2+]i oscillations at
low glucose (Le Marchand & Piston, 2012) but was
without consistent inhibitory effect or even increased their
frequency at high glucose in some cells (Li et al. 2015;
500 s 500 s








Figure 3. Effects of glucose and tolbutamide on [Ca2+]i in
α-cells
A, effects of application of 0.2 mM tolbutamide in three different
α-cells in intact islets exposed to 1 mM glucose. B, as in A but effects
of increasing glucose from 1 to 6 mM. Measurements were made
using fluo-3 in A and the lower trace in B. The other measurements
were performed in α-cells expressing the Ca2+ sensor GCaMP3
under the proglucagon promoter.
Quesada et al. 1999; MacDonald et al. 2007), whereas
complete inhibition of the β-cells was observed. The
latter difference may be related to the fact that diazoxide’s
capacity to activate the KATP channels is diminished by
high intracellular ATP concentration (Zunkler et al. 1988),
a concept that would be consistent with the strong tonic
inhibition of KATP channels in α-cells.
Comparison of secretory responses in α- and β-cells
Clearly, the mechanism we propose for glucose- and
tolbutamide-induced inhibition of glucagon secretion
bears a strong resemblance to that which we outline
for biphasic insulin secretion (see Abstract illustration).
During sustained glucose or SU stimulation of
β-cells, there is a time-dependent reduction in action
potential amplitude as well as frequency because of
voltage-dependent and Ca2+-dependent inactivation of
Ca2+ and Na+ channels (partial or complete, respectively).
As in α-cells, exocytosis is β-cells is voltage-dependent
(Gopel et al. 2004) and depends on the local Ca2+
concentration at the release sites (Barg et al. 2001).
This will reduce the rate of insulin because of two
synergistic effects: fewer Ca2+ channels remain to be
activated (inactivation) and there is less voltage-dependent
activation of these (reduced action potential amplitude).
It has been argued that this (in combination with the
depletion of a pool of readily releasable secretory granules)
contributes to the termination of first phase insulin
secretion and that second phase secretion results from
the generation of smaller action potentials (Rorsman &
Ashcroft, 2018). Importantly, the rate of insulin release
during the second phase remains much higher than
the very low rate of release under basal conditions
prior to the initiation of electrical activity. As discussed
below, this is highly significant for an understanding of
why glucose differentially regulates insulin and glucagon
secretion.
In α-cells, the application of tolbutamide and high
glucose also leads to a reduction of action potential
height. As in β-cells, this leads to a decrease in exocytosis.
However, because α-cells (unlike β-cells) are electrically
active at low glucose, ‘basal’ glucagon secretion is high and
the reduction of action potential height therefore leads to
a net inhibition of glucagon secretion (as discussed above)
(see Abstract illustration). In conclusion, time-dependent
changes in action potential frequency and amplitude shape
the secretory responses in both β- and α-cells.
KATP channels also control glucagon
secretion in humans
The model outlined above for the regulation of glucagon
secretion is largely based on studies of α-cells in isolated
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mouse islets. However, key elements of the model
have been confirmed in isolated human pancreatic
islets; whereas tolbutamide depolarizes human α-cells
and inhibits glucagon secretion (Ramracheya et al.
2010), low concentrations of diazoxide reverse the
glucagonostatic effect of high glucose (MacDonald et al.
2007). Importantly, there are also clinical data to support
the model. In healthy individuals, glucagon secretion
increases when plasma glucose is lowered to 3.6 mM
(by administration of exogenous insulin; Banarer et al.
(2002)). Parenthetically, the fact that insulin is commonly
used to produce hypoglycaemia and stimulate glucagon
secretion militates against the prevailing dogma that
insulin is a major glucagonostatic factor (Unger & Orci,
2010). This stimulation is abolished in the presence
of tolbutamide, suggesting that counter-regulatory
glucagon secretion is mediated by an increase in KATP
channel activity. Notably, tolbutamide only affects
glucagon secretion at low glucose and it is ineffective
under normoglycaemic conditions (Fig. 4A), presumably
because the KATP channels are already (nearly) maximally
inhibited under the latter condition. Application of
tolbutamide leads to stimulation of the insulin secretion
rate (estimated from the increase in plasma C-peptide,
which reflects endogenous insulin release; exogenous
insulin will not contain C-peptide); this effect was
strongest under normoglycaemic conditions and in terms
of absolute magnitude it was reduced by nearly 50%
following induction of hypoglycaemia (Fig. 4B). Although
the data were interpreted in terms of intra-islet insulin
exerting a glucagonostatic effect (Banarer et al. 2002), the
findings that KATP channels are present in human α-cells
and control glucagon secretion rather suggest that it
reflects a direct effect of the SU on the α-cells. In agreement
with this idea, the KATP channel activator diazoxide also
inhibits glucagon secretion evoked by hypoglycaemia
without affecting intra-islet insulin secretion (again
estimated from C-peptide measurements) (Fig. 4C–D)
(Raju & Cryer, 2005). Diazoxide reduced C-peptide by
50% whilst not affecting glucagon secretion when applied
under normoglycaemic conditions. By contrast, when
the KATP channel opener was tested after induction of
hypoglycaemia there was no effect on endogenous insulin
release and yet counter-regulatory glucagon secretion was
reduced. The finding that both KATP channel activators
and inhibitors inhibit glucagon secretion becomes under-
standable from the bell-shaped relationship documented
in vitro (Zhang et al. 2013).
Islet KATP channels and diabetes:
pathophysiological and therapeutic
implications
There are – broadly speaking – two forms of diabetes:
type 1 diabetes (T1D) that has been attributed to
the autoimmune destruction of the β-cells (resulting
in a dramatically reduced insulin content) (Brissova
et al. 2018) and type-2 diabetes (T2D) that is caused
by insufficient insulin secretion (often but not always
combined with insulin resistance) (Ahlqvist et al. 2018).
In T2D, the capacity of glucose to evoke insulin
Figure 4. Effects of tolbutamide and diazoxide
on glucagon secretion in clinical studies
A–B, glucagon (A) and insulin secretion rate (B;
estimated from the release of C-peptide, a proxy
for endogenous insulin secretion) measured in the
absence and presence of tolbutamide (1 g/h
intravenously) under essentially normo- (4.7 mM)
and hypoglycaemic (3 mM) conditions.
Hypoglycaemia induced by administering insulin
intravenously (1.5 or 6 pmol kg-1 min-1). Data from
Banarer et al. (2002) (redrawn). C–D, as in A–B but
measured in the absence and presence of
diazoxide (6 mg kg−1, orally). Data from Raju &
Cryer (2005) (redrawn).
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secretion is selectively reduced whereas the insulinotropic
capacity of other secretagogues like GLP-1 and arginine
are maintained (Ward et al. 1984; Deacon & Holst,
2013). These compounds stimulate insulin secretion by
mechanisms that are (partially or wholly) independent
of KATP channel closure (Shigeto et al. 2015). This
raises the interesting possibility that the impairment of
glucose-induced insulin secretion in T2D is caused by the
failure of glucose to inhibit the KATP channel (possibly
reflecting impaired mitochondrial ATP production) (Del
Guerra et al. 2005). This would account for the therapeutic
capacity of the KATP channel-blocking SUs; by closing
the KATP channel they restore action potential firing and
insulin secretion in T2D patients. A problem with the SUs
is that they, because of their mode of action (inhibiting the
KATP channels by a direct/non-metabolic effect), disable
the normal feedback control of β-cell electrical activity
and insulin secretion. Consequently, insulin secretion
remains inappropriately stimulated even after normal
plasma glucose has been restored or even fallen below
the normal range (see Fig. 4B).
Although it has attracted much less attention, both
T1D and T2D are also associated with defective glucagon
secretion. The dysregulation is dual: too much glucagon
is secreted under hyperglycaemic conditions (when it
is not needed) and too little is released in response to
hypoglycaemia (when it is needed) (Muller et al. 1970).
A similar dysregulation is seen in 50% of human islet
preparations from donors diagnosed with T2D (Zhang
et al. 2013): in these preparations glucagon secretion at
1 mM glucose is lower than in islets from non-diabetic
donors and increasing glucose stimulates rather than
inhibits glucagon release (Fig. 5A). These defects can
be recapitulated in islets from non-diabetic donors by
exposure to low concentrations of diazoxide (Fig. 5B) or
by metabolical poisoning (Zhang et al. 2013), suggesting
that the glucagon secretion defects in T2D result from
an increase in KATP channel activity due to metabolic
derangement in theα-cell interfering with ATP production
(Knudsen et al. 2019). In patients with T1D, glucagon
secretion is completely refractory to changes in plasma
glucose (Gerich et al. 1973).This may be also due to an
increase in α-cell KATP channel activity. This would explain
the observation that a high dose of the SU glimepiride
stimulates glucagon secretion in T1D patients whereas
it slightly inhibits the release of the hormone in healthy
individuals (Cooperberg & Cryer, 2009) (Fig. 5C). We
attribute the weak effect of glimepiride in the healthy
controls to the fact that this experiment was performed
under normoglycaemic conditions (5 mM).
Based on the bell-shaped relationship between KATP
channel activity and glucagon secretion, we propose that
glucagon secretion is suppressed under hypoglycaemic
conditions in diabetic patients because KATP channel
activity has increased beyond the optimal range (Fig. 5D).
The severity of the metabolic defect will determine the
clinical phenotype and range (depending on the increase
in KATP channel activity) between nearly normal (i), high
rate of glucagon secretion but no effect of glucose (ii),
inverted glucose responses (iii) and low rate of glucagon
secretion with no effect of glucose at all (iv) as illustrated
schematically in Fig. 5D (inset).
These considerations suggest that it may be possible
to pharmacologically restore normal glucose regulation
of glucagon secretion using SUs. There is evidence from
studies in isolated islets from donors diagnosed with T2D
that this works in vitro (Zhang et al. 2013). It will be
interesting to establish whether this is also the case in
T1D islets. However, for SUs to be effective in patients
with diabetes and impaired glucagon secretion, they
must be carefully dosed to reduce KATP channel activity
into the range where glucagon secretion is maximal;
the high concentrations normally used for stimulating
insulin secretion will probably inhibit glucagon secretion
by producing complete inhibition of the KATP channels. In
fact, such an effect may contribute to the (unacceptably)
high risk of hypoglycaemia associated with SU therapy
(Ruan et al. 2020), which is one of the reasons these
compounds are no longer favoured in T2D therapy
(Khunti et al. 2018). This is because not only do they
stimulate the release of insulin under hypoglycaemic
conditions (see above), they also abolish the body’s
counter-regulatory response.
We point out that the bell-shaped relationship between
K+ channel activity and glucagon secretion is agnostic
with regard to the type of K+ channels involved. We have
previously proposed that the resting K+ conductance in
α-cells may be a mosaic of different K+ channel activities
(Briant et al. 2016). In healthy α-cells, KATP channels pre-
dominate but the situation might be different after the
onset of diabetes (Fig. 5E). Indeed, T2D is associated with
hypersecretion of somatostatin at low glucose (Vergari
et al. 2020). Somatostatin inhibits glucagon secretion
by several mechanisms including the activation of G
protein-coupled inward-rectifying K+ channels (GIRK)
and a direct effect on exocytosis (Rorsman & Huising,
2018). Interestingly, the somatostatin receptor (SSTR)
antagonist CYN154806 restores glucagon secretion at
1 mM glucose in diabetic mice and in some islet pre-
parations from donors with T2D (Vergari et al. 2020).
In such patients, blocking the KATP channel component,
low-dose SUs might lower the resting K+ conductance
sufficiently to stimulate secretion at 1 mM glucose but
it would not correct the suppression due to inhibition of
exocytosis. This would account for the fact that SUs, whilst
restoring normal glucose regulation, fail to normalise
glucagon secretion at 1 mM glucose to the level seen in islets
from healthy mice/organ donors without T2D (Knudsen
et al. 2019). Conversely, an SSTR antagonist would pre-
vent activation of the GIRK channels and reverse the
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effect on exocytosis but not the metabolic defect leading
to increased KATP channel activity. Thus, a combination
of SSTR antagonists and SUs may be required to fully
restore normal metabolic regulation of glucagon secretion
in patients with T1D and T2D.
Yin and Yang of K+ channel activity
In this Topical Review we show – based on observations
in pancreatic α- and β-cells – that K+ channel
closure has a dual effect on electrical excitability
and hormone/neurotransmitter release. Normally, a
reduction of K+ channel activity increases electrical
excitability by producing membrane depolarization and
increasing the membrane resistance (as exemplified by
the β-cell). However, K+ channel activity must not be
reduced too much; excessive and maintained membrane
depolarization may lead to voltage-dependent inactivation
of the membrane conductances involved in action
potential firing, resulting in a paradoxical decrease in
electrical excitability (as exemplified by the α-cell). Under
these conditions, (high membrane) resistance is indeed
Figure 5. KATP channels and dysregulation of glucagon secretion in diabetes
A, relative change in glucagon secretion measured in islets from healthy donors (n = 40) and donors diagnosed
with T2D (n = 10) in response to an elevation of glucose from 1 to 20 mM. Responses in T2D islets fell into two
groups; one with normal regulation (n = 5) and one with inverted regulation (n = 5). B, glucagon secretion in
islets from two healthy organ donors at 1 and 6 mM glucose in the absence and presence of 2 μM diazoxide. C, net
change of plasma glucagon measured in healthy individuals and in patients with T1D 4 h after administration of
the SU glimepiride (4 mg, orally). Data from Cooperberg & Cryer (2009) (redrawn). D, relationship between total
whole-cell K channel conductance (G) and glucagon secretion (continuous curve) in T2D patients with normal KATP
channel regulation (i) and with small (ii), moderate (iii) or large (iv) increases in KATP channel activity. The arrows
indicate the changes in glucagon secretion produced by an elevation of glucose from 1 to 6 mM. The bar graphs
(Inset) show the predicted effects of increasing glucose with variable degrees of basal KATP channel hyperactivity. E,
schematic illustrating the effects of SU or an SSTR antagonist. The α-cell is initially repolarized (top trace) because
resting whole-cell K+ conductance in excess of background (G) is increased from the optimal 0.1 nS to 0.2 nS
(see Fig. 2). This increase may result from either an increase in KATP (grey; due to a metabolic defect in the α-cells)
and/or GIRK (red; due to increased somatostatin release from δ-cells) channel activity. Inhibition of KATP channels
with SU (middle) or GIRK channels with an SSTR antagonist reduces G to the 0.1 nS, which is optimal for α-cell
electrical activity and glucagon secretion.
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futile. Thus, there is a yin and yang of K+ channel activity
and electrical excitability. Although our argument here
focuses on the role of KATP channels and the pancreatic islet
α- and β-cells, the concept might be equally applicable to
other types of K+ channel and other cell types/tissues.
For example, in the brain’s supra-chiasmatic nucleus,
closure of small conductance Ca2+-activated K+-channels
causes membrane depolarization and yet suppresses action
potential firing (Belle et al. 2009). Our data suggest that the
glucagon-secreting α-cells are regulated similarly and do
not obey conventional electrophysiological expectations.
The way forward
We acknowledge that this Topical Review has a slant
towards electrophysiological explanations. However, this
does not mean that events beneath the plasma membrane
are irrelevant or uninteresting! As we have tried to discuss
above, there must be metabolic differences between the
β- and α-cells that ensure that ATP is maintained at
sufficiently high levels to keep the KATP channels almost
fully closed even during protracted hypoglycaemia to
ensure continuous release of glucagon but how this occurs
is not known. If this mechanism becomes defective in
diabetes, it might explain the dysregulation of glucagon
secretion associated with the disease and the loss of
appropriate counter-regulatory glucagon secretion in
some of the patients.
It is currently unknown whether the glucagon secretion
defects associated with diabetes develop in α-cells
independently of the disruption of β-cell function or
whether they are a consequence of diabetes. Data
from mouse models of diabetes suggest that the
dysregulation of glucagon secretion is secondary to
hyperglycaemia-induced intracellular acidification of the
α-cell that interferes with mitochondrial ATP production
that in turn results in KATP channel activation and
suppression of glucagon secretion (Knudsen et al. 2019). It
will be important to establish whether this also applies to
human α-cells and whether these defects can be reversed
by pharmacological interventions. The finding that low
concentrations of SUs partially correct the glucagon
secretion in diabetic islets in vitro suggests that this is
feasible (Zhang et al. 2013) but whether these findings
can be translated into improved clinical management
remains to be established in clinical trials. Importantly,
the SUs must be carefully dosed to reduce KATP channel
activity by 50% (IC50) as higher concentrations inhibit
glucagon secretion (Zhang et al. 2013). A stable plasma
concentration around the IC50 is difficult to achieve
therapeutically with currently available SUs and small
changes in the concentration will have large effects on KATP
channel activity/glucagon secretion. Successful translation
into the clinic may therefore require a KATP channel blocker
with a mode of action distinct from that of the currently
used lipophilic SUs that reach the binding site following
solvation in the plasma membrane (Zunkler et al. 1989).
Finally, impaired counter-regulatory glucagon secretion
with the risk of severe (potentially fatal) hypoglycaemia
represents a barrier towards optimal glycaemic control.
The only effective treatment available for recurrent
life-threatening hypoglycaemia is islet or pancreas trans-
plantation but the need for lifelong immunosuppression
makes this a last resort (Harlan, 2016). Importantly,
not all patients with diabetes experience severe hypo-
glycaemia and 80% of patients with T2D and 60% of
patients with T1D seem protected even after 5 years of
insulin therapy (UK Hypoglycaemia Study(Group, 2007).
Why hypoglycaemia only affects some patients is not
known but it is tempting to speculate that this sub-
group is genetically predisposed. Whilst there has been
much progress in the understanding of the genetic basis
of the insulin secretion defects in T2D (Mahajan et al.
2018), hardly anything is known about the genetics of
the glucagon secretion defects. With the advent of human
iPSC-derived glucose-responsive α-cells with electro-
physiological properties that closely resemble those of
primary human α-cells (Peterson et al. 2020), it might
be possible to compare glucagon secretion in response to
hypoglycaemia and its relationship to electrical activity in
α-cells derived from diabetes patients with good glycaemic
control and those with an elevated risk of hypoglycaemia.
This represents an exciting – but challenging – area
of future research into the dysregulation of glucagon
secretion in diabetes.
References
Ahlqvist E, Storm P, Karajamaki A, Martinell M, Dorkhan M,
Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P,
Wessman Y, Shaat N, Spegel P, Mulder H, Lindholm E,
Melander O, Hansson O, Malmqvist U, Lernmark A, Lahti
K, Forsen T, Tuomi T, Rosengren AH & Groop L (2018).
Novel subgroups of adult-onset diabetes and their
association with outcomes: a data-driven cluster analysis of
six variables. Lancet Diabetes Endocrinol 6, 361–369.
Ashcroft FM (2007). The Walter B. Cannon physiology in
perspective lecture, 2007. ATP-sensitive K+ channels and
disease: from molecule to malady. Am J Physiol Endocrinol
Metab 293, E880-889.
Babinsky VN, Hannan FM, Ramracheya RD, Zhang Q, Nesbit
MA, Hugill A, Bentley L, Hough TA, Joynson E, Stewart M,
Aggarwal A, Prinz-Wohlgenannt M, Gorvin CM, Kallay E,
Wells S, Cox RD, Richards D, Rorsman P & Thakker RV
(2017). Mutant Mice With Calcium-Sensing Receptor
Activation Have Hyperglycemia That Is Rectified by
Calcilytic Therapy. Endocrinology 158, 2486–2502.
Banarer S, McGregor VP & Cryer PE (2002). Intraislet
hyperinsulinemia prevents the glucagon response to
hypoglycemia despite an intact autonomic response.
Diabetes 51, 958–965.
C© 2020 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
J Physiol 598.21 KATP channels in pancreatic α- and β-cells 4777
Barg S, Galvanovskis J, Gopel SO, Rorsman P & Eliasson L
(2000). Tight coupling between electrical activity and
exocytosis in mouse glucagon-secreting alpha-cells. Diabetes
49, 1500–1510.
Barg S, Ma X, Eliasson L, Galvanovskis J, Gopel SO,
Obermuller S, Platzer J, Renstrom E, Trus M, Atlas D,
Striessnig J & Rorsman P (2001). Fast exocytosis with few
Ca(2+) channels in insulin-secreting mouse pancreatic B
cells. Biophys J 81, 3308–3323.
Basco D, Zhang Q, Salehi A, Tarasov A, Dolci W, Herrera P,
Spiliotis I, Berney X, Tarussio D, Rorsman P & Thorens B
(2018). alpha-cell glucokinase suppresses glucose-regulated
glucagon secretion. Nat Commun 9, 546.
Belle MD, Diekman CO, Forger DB & Piggins HD (2009).
Daily electrical silencing in the mammalian circadian clock.
Science 326, 281–284.
Bokvist K, Olsen HL, Hoy M, Gotfredsen CF, Holmes WF,
Buschard K, Rorsman P & Gromada J (1999).
Characterisation of sulphonylurea and ATP-regulated K+
channels in rat pancreatic A-cells. Pflugers Arch 438,
428–436.
Braun M, Ramracheya R, Bengtsson M, Zhang Q,
Karanauskaite J, Partridge C, Johnson PR & Rorsman P
(2008). Voltage-gated ion channels in human pancreatic
beta-cells: electrophysiological characterization and role in
insulin secretion. Diabetes 57, 1618–1628.
Braun M & Rorsman P (2010). The glucagon-producing alpha
cell: an electrophysiologically exceptional cell. Diabetologia
53, 1827–1830.
Briant L, Salehi A, Vergari E, Zhang Q & Rorsman P (2016).
Glucagon secretion from pancreatic alpha-cells. Ups J Med
Sci 121, 113–119.
Briant LJ, Zhang Q, Vergari E, Kellard JA, Rodriguez B,
Ashcroft FM & Rorsman P (2017). Functional identification
of islet cell types by electrophysiological fingerprinting. J R
Soc Interface 14.
Briant LJB, Dodd MS, Chibalina MV, Rorsman NJG, Johnson
PRV, Carmeliet P, Rorsman P & Knudsen JG (2018).
CPT1a-dependent long-chain fatty acid oxidation
contributes to maintaining glucagon secretion from
pancreatic islets. Cell Rep 23, 3300–3311.
Brissova M, Haliyur R, Saunders D, Shrestha S, Dai C, Blodgett
DM, Bottino R, Campbell-Thompson M, Aramandla R,
Poffenberger G, Lindner J, Pan FC, von Herrath MG,
Greiner DL, Shultz LD, Sanyoura M, Philipson LH, Atkinson
M, Harlan DM, Levy SE, Prasad N, Stein R & Powers AC
(2018). alpha cell function and gene expression are
compromised in type 1 diabetes. Cell Rep 22, 2667–2676.
Cheng-Xue R, Gomez-Ruiz A, Antoine N, Noel LA, Chae HY,
Ravier MA, Chimienti F, Schuit FC & Gilon P (2013).
Tolbutamide controls glucagon release from mouse islets
differently than glucose: involvement of K(ATP) channels
from both alpha-cells and delta-cells. Diabetes 62,
1612–1622.
Cook DL & Hales CN (1984). Intracellular ATP directly blocks
K+ channels in pancreatic B-cells. Nature 311, 271–273.
Cooperberg BA & Cryer PE (2009). Beta-cell-mediated
signaling predominates over direct alpha-cell signaling in the
regulation of glucagon secretion in humans. Diabetes Care
32, 2275–2280.
De Marinis YZ, Salehi A, Ward CE, Zhang Q, Abdulkader F,
Bengtsson M, Braha O, Braun M, Ramracheya R, Amisten S,
Habib AM, Moritoh Y, Zhang E, Reimann F, Rosengren A,
Shibasaki T, Gribble F, Renstrom E, Seino S, Eliasson L &
Rorsman P (2010). GLP-1 inhibits and adrenaline stimulates
glucagon release by differential modulation of N- and L-type
Ca2+ channel-dependent exocytosis. Cell Metab 11,
543–553.
Deacon CF & Holst JJ (2013). Dipeptidyl peptidase-4 inhibitors
for the treatment of type 2 diabetes: comparison, efficacy
and safety. Expert Opin Pharmacother 14, 2047–2058.
Deivasikamani V, Dhayalan S, Abudushalamu Y, Mughal R,
Visnagri A, Cuthbertson K, Scragg JL, Munsey TS,
Viswambharan H, Muraki K, Foster R, Sivaprasadarao A,
Kearney MT, Beech DJ & Sukumar P (2019). Piezo1 channel
activation mimics high glucose as a stimulator of insulin
release. Sci Rep 9, 16876.
Del Guerra S, Lupi R, Marselli L, Masini M, Bugliani M, Sbrana
S, Torri S, Pollera M, Boggi U, Mosca F, Del Prato S &
Marchetti P (2005). Functional and molecular defects of
pancreatic islets in human type 2 diabetes. Diabetes 54,
727–735.
DiGruccio MR, Mawla AM, Donaldson CJ, Noguchi GM,
Vaughan J, Cowing-Zitron C, van der Meulen T & Huising
MO (2016). Comprehensive alpha, beta and delta cell
transcriptomes reveal that ghrelin selectively activates delta
cells and promotes somatostatin release from pancreatic
islets. Mol Metab 5, 449–458.
Dunne MJ & Petersen OH (1986). Intracellular ADP activates
K+ channels that are inhibited by ATP in an
insulin-secreting cell line. FEBS Lett 208, 59–62.
Fenwick EM, Marty A & Neher E (1982). A patch-clamp study
of bovine chromaffin cells and of their sensitivity to
acetylcholine. J Physiol 331, 577–597.
Frayn KN & Evans R (2019). Human Metabolism: A Regulatory
Perspective. Wiley Blackwell’s, Oxford.
Gerich JE, Langlois M, Noacco C, Karam JH & Forsham PH
(1973). Lack of glucagon response to hypoglycemia in
diabetes: evidence for an intrinsic pancreatic alpha cell
defect. Science 182, 171–173.
Godazgar M, Zhang Q, Chibalina MV & Rorsman P (2018).
Biphasic voltage-dependent inactivation of human NaV 1.3,
1.6 and 1.7 Na(+) channels expressed in rodent
insulin-secreting cells. J Physiol 596, 1601–1626.
Gopel S, Kanno T, Barg S, Galvanovskis J & Rorsman P (1999).
Voltage-gated and resting membrane currents recorded from
B-cells in intact mouse pancreatic islets. J Physiol 521 Pt 3,
717–728.
Gopel S, Zhang Q, Eliasson L, Ma XS, Galvanovskis J, Kanno T,
Salehi A & Rorsman P (2004). Capacitance measurements of
exocytosis in mouse pancreatic alpha-, beta- and delta-cells
within intact islets of Langerhans. J Physiol 556, 711–726.
Gopel SO, Kanno T, Barg S & Rorsman P (2000). Patch-clamp
characterisation of somatostatin-secreting -cells in intact
mouse pancreatic islets. J Physiol 528, 497–507.
Gromada J, Ma XS, Hoy M, Bokvist K, Salehi A, Berggren PO &
Rorsman P (2004). ATP-sensitive K+ channel-dependent
regulation of glucagon release and electrical actiflty by
glucose in wild-type and SUR1(-/-) mouse alpha-cells.
Diabetes 53, S181-S189.
C© 2020 The Authors. The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
4778 Q. Zhang and others J Physiol 598.21
Hamill OP, Marty A, Neher E, Sakmann B & Sigworth FJ
(1981). Improved patch-clamp techniques for
high-resolution current recording from cells and cell-free
membrane patches. Pflugers Arch 391, 85–100.
Hamilton A, Zhang Q, Salehi A, Willems M, Knudsen JG,
Ringgaard AK, Chapman CE, Gonzalez-Alvarez A, Surdo
NC, Zaccolo M, Basco D, Johnson PRV, Ramracheya R,
Rutter GA, Galione A, Rorsman P & Tarasov AI (2018).
Adrenaline Stimulates Glucagon Secretion by
Tpc2-Dependent Ca(2+) Mobilization From Acidic Stores
in Pancreatic alpha-Cells. Diabetes 67,
1128–1139.
Harlan DM (2016). Islet Transplantation for Hypoglycemia
Unawareness/Severe Hypoglycemia: Caveat Emptor.
Diabetes Care 39, 1072–1074.
Hauge-Evans AC, King AJ, Carmignac D, Richardson CC,
Robinson IC, Low MJ, Christie MR, Persaud SJ & Jones PM
(2009). Somatostatin secreted by islet delta-cells fulfills
multiple roles as a paracrine regulator of islet function.
Diabetes 58, 403–411.
Henquin JC (1988). ATP-sensitive K+ channels may control
glucose-induced electrical activity in pancreatic B-cells.
Biochem Biophys Res Commun 156, 769–775.
Henquin JC & Meissner HP (1982). Opposite effects of
tolbutamide and diazoxide on 86Rb+ fluxes and membrane
potential in pancreatic B cells. Biochem Pharmacol 31,
1407–1415.
Houamed KM, Sweet IR & Satin LS (2010). BK channels
mediate a novel ionic mechanism that regulates
glucose-dependent electrical activity and insulin secretion in
mouse pancreatic beta-cells. J Physiol 588,
3511–3523.
Huang Y, Hu D, Huang C & Nichols CG (2019). Genetic
Discovery of ATP-Sensitive K(+) Channels in
Cardiovascular Diseases. Circ Arrhythm Electrophysiol 12,
e007322.
Hughes JW, Ustione A, Lavagnino Z & Piston DW (2018).
Regulation of islet glucagon secretion: Beyond calcium.
Diabetes Obes Metab 20 Suppl 2, 127–136.
Jacobson DA, Kuznetsov A, Lopez JP, Kash S, Ammala CE &
Philipson LH (2007). Kv2.1 ablation alters glucose-induced
islet electrical activity, enhancing insulin secretion. Cell
Metab 6, 229–235.
Kakei M, Kelly RP, Ashcroft SJ & Ashcroft FM (1986). The
ATP-sensitivity of K+ channels in rat pancreatic B-cells is
modulated by ADP. FEBS Lett 208, 63–66.
Kanno T, Rorsman P & Gopel SO (2002). Glucose-dependent
regulation of rhythmic action potential firing in pancreatic
beta-cells by K(ATP)-channel modulation. J Physiol 545,
501–507.
Kellard JA, Rorsman NJG, Hill TG, Armour SL, van der Bunt
M, Rorsman P, Knudsen JG & Briant LJB (2020). Reduced
somatostatin signalling leads to hypersecretion of glucagon
in mice fed a high-fat diet. Molecular metabolism,
101021.
Khunti K, Chatterjee S, Gerstein HC, Zoungas S & Davies MJ
(2018). Do sulphonylureas still have a place in clinical
practice? Lancet Diabetes Endocrinol 6, 821–832.
Knudsen JG, Hamilton A, Ramracheya R, Tarasov A, Brereton
M, Haythorne e, Chibalina MV, Spegel P, Mulder H, Zhang
Q, Ashcroft FM, Adam J & Rorsman P (2019). Dysregulation
of glucagon secretion by hyperglycemia-induced
sodium-dependent reduction of ATP production. Cell Metab
29, 430–442.e4.
Lai BK, Chae H, Gomez-Ruiz A, Cheng P, Gallo P, Antoine N,
Beauloye C, Jonas JC, Seghers V, Seino S & Gilon P (2018).
Somatostatin Is Only Partly Required for the Glucagonostatic
Effect of Glucose but Is Necessary for the Glucagonostatic
Effect of KATP Channel Blockers. Diabetes 67,
2239–2253.
Le Marchand SJ & Piston DW (2012). Glucose decouples
intracellular Ca2+ activity from glucagon secretion in
mouse pancreatic islet alpha-cells. PLoS One 7, e47084.
Li J, Yu Q, Ahooghalandari P, Gribble FM, Reimann F,
Tengholm A & Gylfe E (2015). Submembrane ATP and
Ca2+ kinetics in alpha-cells: unexpected signaling for
glucagon secretion. FASEB J 29, 3379–3388.
MacDonald PE, De Marinis YZ, Ramracheya R, Salehi A, Ma X,
Johnson PR, Cox R, Eliasson L & Rorsman P (2007). A K
ATP channel-dependent pathway within alpha cells regulates
glucagon release from both rodent and human islets of
Langerhans. PLoS Biol 5, e143.
Mahajan A, Taliun D, Thurner M, Robertson NR, Torres JM,
Rayner NW, Payne AJ, Steinthorsdottir V, Scott RA, Grarup
N, Cook JP, Schmidt EM, Wuttke M, Sarnowski C, Mägi R,
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